Page 8 - Aezs News Today

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright dropped their price objective on shares of Aeterna Zentaris from $2.00 to $1.50 and set a “buy” […]

Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.02), MarketWatch Earnings reports. Aeterna Zentaris had a negative net margin of 156.35% and a negative return on equity of 13.07%. Shares of AEZS […]

StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Aeterna Zentaris stock opened at $0.37 on Friday. The business has a 50 day moving average of $0.36 and a 200-day moving average of $0.47. […]

Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism March 11, 2021 08:05 ET | Source: Aeterna Zentaris Inc Aeterna Zentaris Inc Montreal CANADA – Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of hum...